| 期刊論文| 1. | Denning, D. W.、Pleuvry, A.、Cole, D. C.(2011)。Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis。Bull World Health Organ，89，864-872。   | | 2. | Ohba, H.、Miwa, S.、Shirai, M.(2012)。Clinical characteristics and prognosis of chronic pulmonary aspergillosis。Respir Med，106，724-729。 | | 3. | Nakamota, K.、Takayanagi, N.、Kanauchi, T.、Ishiguro, T.、Yanagisawa, T.、Sugita, Y.(2013)。Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis。Intern Med，52，727-734。 | | 4. | Saito, T.、Fugiuchi, S.、Tao, Y.(2012)。Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan。Infection，40，661-667。 | | 5. | Prasad, R.、Garg, S. R.(2009)。Progressive increase in cavitation with the evolution of fungal ball: A clue to the diagnosis of chronic necrotizing pulmonary aspergillosis。Lung India，26，95-97。 | | 6. | Warris, A.(2014)。The biology of pulmonary aspergillus infections。J Infect，69(Suppl 1)，36-41。 | | 7. | Lass-Florl, C.、Roilides, E.、Loffler, J.、Wilflingseder, D.、Romani, L.(2013)。Minireview: host defence in invasive aspergillosis。Mycoses，56，403-413。 | | 8. | Walsh, T. J.、Anaissie, E. J.、Denning, D. W.(2008)。Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America。Clin Infect Dis，46，327-360。 | | 9. | Wu, C. J.、Lee, H. C.、Lo, H. J.、Ko, W. C.(2011)。Resolution of galacto-mannan antigenemia in a patient receiving oral voriconazole for chronic necrotizing pulmonary aspergillosis。Diagn Microbiol Infect Dis，70，528-530。 | | 10. | Tsubura, E.(1997)。Multicenter clinical trial of itraconazole in the treatment of pulmonary aspergilloma. Pulmonary Aspergilloma Study Group。Kekkaku，72，557-564。 | |